Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiprodil in pediatric tuberous sclerosis complex or focal cortical dysplasia type II
NL-OMON58750Phase 2Completed
- Sponsor
- GRIN Therapeutics, Inc.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of radiprodil in tuberous sclerosis complex (TSC) and Focal Cortical Dysplasia Type 2 (FCD2) (2 arms), sponsored by GRIN Therapeutics, Inc. Primary endpoints: Adverse events and tolerability, Vital signs and 5 more. Started Dec 2023; status: completed.
02
Drugs
radiprodil
03
Conditions
tuberous sclerosis complex (TSC)Focal Cortical Dysplasia Type 2 (FCD2)
Beyond the preview
Go deeper on NL-OMON58750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58750.